CAMP4 wins Australia clearance to start Phase 1/2 trial of CMP-002 in SYNGAP1 disorder
CAMP•Australia clearance for CMP-002 trial
CAMP4 Therapeutics won Australian TGA clearance to start a Phase 1/2 first-in-human trial of CMP-002 for SYNGAP1-related disorder.
Financing milestone tied to second closing
The milestone triggers eligibility for up to USD 50 million in a second private-placement closing, following about USD 50 million raised in 2025.
The second closing is expected within five business days; issuance may include up to 32,721,172 common shares or pre-funded warrants.
5AM Ventures joined the investor group backing the second closing, and Leerink Partners is leading the placement agents.
